Skip to content
Research/Gene Therapy/AAV9-Follistatin Gene Therapy

AAV9-Follistatin Gene Therapy

AAV9-Follistatin gene therapy involves using an adeno-associated virus (AAV9) vector to deliver the follistatin gene into cells. Follistatin is a protein that inhibits myostatin, a growth factor that limits muscle growth. This therapy aims to enhance muscle mass and strength, which could be beneficial for age-related muscle loss and other muscle-wasting conditions, contributing to improved longevity and healthspan.

Intelligence Profile

Safety Profile

Currently, there is no specific safety profile information provided for AAV9-Follistatin Gene Therapy based on the evidence available. None of the studies or articles listed directly address the safety, side effects, contraindications, or interactions for this therapy.

Given the recruiting status of the clinical trial NCT07443826, it seems that research into this gene therapy is ongoing, likely indicating that comprehensive safety data might still be under development. Generally, gene therapies require careful assessment of immune responses, long-term effects, and potential integration into the host genome, but specific data for AAV9-Follistatin are not available in the provided material.

In clinical trials, possible side effects and contraindications are typically monitored closely, but detailed findings would be necessary for a conclusive safety profile.

Thus, further evidence is needed to outline detailed safety information for AAV9-Follistatin Gene Therapy. Until more specific trial results are published, practitioners and patients should proceed with caution.

Disclaimer: This content is for informational purposes and not a substitute for professional medical advice. Always consult healthcare providers for personal medical decisions.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.